Expression of bcl-2 — protein in small cell lung cancer

Ulrich Kaiser(University of Applied Sciences Landshut), K. Havemann(Philipps University of Marburg), Е А Коган(Sechenov University), K Neumann(Philipps University of Marburg), U. Haag(Heidelberg University), M. Schilli(Philipps University of Marburg), Hans Kreipe(Medizinische Hochschule Hannover)

Lung Cancer

August 1, 1996

10.1016/0169-5002(96)00568-5

Cited by 104

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

|Modern Pathology|2016|281

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

|Blood|2021|170